Toapanta-Yanchapaxi L, López-Velázquez JA, Uribe M, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 487-492
Archivo PDF: 135.30 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol 2012; 2012: 480309.

2. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-83.

3. Kappus MR, Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. Clin Gastroenterol Hepatol 2012; 10: 1208-19.

4. Zhan T, Stremmel W. The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int 2012; 109: 180-7.

5. Alfawaz HA, Aljumah AA. What improves minimal hepatic encephalopathy: probiotic yogurt, protein restriction or nonabsorbable disaccharides? Saudi J Gastroenterol 2012; 18: 153-4.

6. Gad YZ, Zaher AA, Moussa NH, El-desoky AEE, Al-Adarosy HA. Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology 2011; 12: 58-61.

7. Moscucci F, Nardelli S, Pentassuglio I, Pasquale C, Ridola L, Merli M, Riggio O. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs healthrelated quality of life in cirrhotic patients. Liver Int 2011; 31: 1505-10.

8. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a metaanalysis. Eur J Gastroenterol Hepatol 2011; 23: 1250-7.

9. Bass N, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 12: 1071-81.

10. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and healthrelated quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-16.

11. Holte K, Krag A, Gluud LL. Systematic review and metaanalysis of randomized trials on probiotics for hepatic encephalopathy. Hepatology research: the official journal of the Japan Society of Hepatology 2012; 42: 1008-15.

12. Wunsch E, Szymanik B, Post M, Marlicz W, Myd³owska M, Milkiewicz P. Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver Int 2011; 31: 980-4.

13. Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.

14. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-9.

15. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-87.

16. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-77.

17. Holte K, Krag A, Gluud LL. Systematic review and metaanalysis of randomized trials on probiotics for hepatic encephalopathy. Hepatology research: the official journal of the Japan Society of Hepatology 2012; 42: 1008-15.

18. Bai M, Yang Z, Qi X, Fan D, Han G. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013. Doi:10.1111/jgh.12142.